NO960907L - Immunomoduleringssammensetninger fra galle - Google Patents

Immunomoduleringssammensetninger fra galle

Info

Publication number
NO960907L
NO960907L NO960907A NO960907A NO960907L NO 960907 L NO960907 L NO 960907L NO 960907 A NO960907 A NO 960907A NO 960907 A NO960907 A NO 960907A NO 960907 L NO960907 L NO 960907L
Authority
NO
Norway
Prior art keywords
immunomodulator
bile
composition
immunomodulation
compositions
Prior art date
Application number
NO960907A
Other languages
English (en)
Other versions
NO960907D0 (no
Inventor
Romeo Rang
Original Assignee
Imutec Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imutec Corp filed Critical Imutec Corp
Publication of NO960907D0 publication Critical patent/NO960907D0/no
Publication of NO960907L publication Critical patent/NO960907L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En sammensetning for anvendelse som en immunomodulator omfattende komponenter med lav molekylvekt på mindre enn 3000 dalton og som har følgende egenskaper: a) kan ekstraheres fra dyregaller; b) kan stimulere monocyter og makrofager in vitro; c) kan modulere tumomekrosefaktorproduksjon; d) inneholder ingen målbar IL-1 a, IL-1 b, TNF, IL-6, IL-8, IL-4, GM-CSF eller IFN-gamma; e) har en anti-proliferativ virkning i en malign musehydbridoma cellelinje; f) viser ingen cytotoksisitet overfor humane perifere blodmononukleære celler og g) er ikke et endotoksin, og en fremgangsmåte for fremstilling av sammensetning og anvendelse som en immunomodulator, er beskrevet.
NO960907A 1993-09-09 1996-03-06 Immunomoduleringssammensetninger fra galle NO960907L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11826993A 1993-09-09 1993-09-09
US15530393A 1993-11-22 1993-11-22
US23172694A 1994-04-22 1994-04-22
PCT/CA1994/000494 WO1995007089A1 (en) 1993-09-09 1994-09-09 Immunomodulating compositions from bile

Publications (2)

Publication Number Publication Date
NO960907D0 NO960907D0 (no) 1996-03-06
NO960907L true NO960907L (no) 1996-04-30

Family

ID=27382133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960907A NO960907L (no) 1993-09-09 1996-03-06 Immunomoduleringssammensetninger fra galle

Country Status (14)

Country Link
US (1) US6280774B1 (no)
EP (1) EP0717631B1 (no)
JP (1) JP4708511B2 (no)
KR (1) KR100260110B1 (no)
CN (1) CN1132586C (no)
AT (1) ATE244570T1 (no)
AU (1) AU7648994A (no)
CA (1) CA2171281C (no)
DE (1) DE69432930T2 (no)
ES (1) ES2207639T3 (no)
FI (1) FI961109A7 (no)
NO (1) NO960907L (no)
NZ (1) NZ273258A (no)
WO (1) WO1995007089A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980703088A (ko) * 1995-03-16 1998-09-05 라카일레 지, 필리페 신규의 침전탄산칼슘 안료를 포함하는 잉크젯 기록지
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
CA2206047A1 (en) * 1997-05-23 1998-11-23 Romeo Rang (Deceased) Immunomodulating compositions for the treatment of viral disorders
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20040101511A1 (en) * 2000-11-08 2004-05-27 Young Aiping H Combination preparation of a biological response modifier and an anticancer agent and uses thereof
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
JP4274469B2 (ja) * 2004-01-20 2009-06-10 Ｏｋｉセミコンダクタ株式会社 データ取り込みクロック補正回路
EP1863520B1 (en) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Use of interleukin 17e for the treatment of cancer
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
CN101629951B (zh) * 2009-08-20 2013-01-02 吴广印 一种人胎盘组织液抗炎作用检测方法
US8338383B1 (en) 2012-02-17 2012-12-25 Gregory Jr Daniel Tyree Use of immunomodulators for the treatment of cancer
US8236354B1 (en) * 2012-02-17 2012-08-07 ZOR Pharmaceuticals, LLC Use of immunomodulators for the treatment of cancer
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
KR20250171471A (ko) 2019-05-10 2025-12-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 장 박테리아 담즙산 대사의 소분자 조정제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US4585762A (en) 1982-07-30 1986-04-29 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same
JPS5984824A (ja) 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US4916249A (en) 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
IE59777B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5087721A (en) 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
WO1989006977A1 (en) 1988-02-04 1989-08-10 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
EP0356765A3 (en) 1988-08-19 1991-08-07 Takeda Chemical Industries, Ltd. Carboxylic acid derivatives, their production and use
CA2001532A1 (en) 1988-10-27 1990-04-27 Hiroaki Nomura Lipids, their production and use
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
GB8928580D0 (en) 1989-12-19 1990-02-21 Scras 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives
US5369097A (en) 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents

Also Published As

Publication number Publication date
JPH09502706A (ja) 1997-03-18
HK1007922A1 (en) 1999-04-30
CN1136777A (zh) 1996-11-27
ATE244570T1 (de) 2003-07-15
ES2207639T3 (es) 2004-06-01
EP0717631A1 (en) 1996-06-26
FI961109A0 (fi) 1996-03-08
DE69432930T2 (de) 2004-05-06
EP0717631B1 (en) 2003-07-09
JP4708511B2 (ja) 2011-06-22
CA2171281A1 (en) 1995-03-16
KR100260110B1 (ko) 2000-07-01
US6280774B1 (en) 2001-08-28
AU7648994A (en) 1995-03-27
CA2171281C (en) 1998-12-29
WO1995007089A1 (en) 1995-03-16
NO960907D0 (no) 1996-03-06
CN1132586C (zh) 2003-12-31
NZ273258A (en) 2000-01-28
FI961109L (fi) 1996-05-06
FI961109A7 (fi) 1996-05-06
DE69432930D1 (de) 2003-08-14

Similar Documents

Publication Publication Date Title
NO960907L (no) Immunomoduleringssammensetninger fra galle
NO974257L (no) Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer
Ghoneum et al. Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran)
Sempowski et al. Interleukin‐4 and interferon‐γ discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets
Bhalla et al. Differential effects of 1, 25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production
Khalil et al. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat.
Harada et al. IFN-γ induction by SCG, 1, 3-β-D-glucan from Sparassis crispa, in DBA/2 mice in vitro
Saklatvala Characterization of catabolin, the major product of pig synovial tissue that induces resorption of cartilage proteoglycan in vitro
Okai et al. Possible immunodulating activities in an extract of edible brown alga, Hijikia fusiforme (Hijiki)
Kumalasari et al. Immunomodulatory activity of Bengkoang (Pachyrhizus erosus) fiber extract in vitro and in vivo
Fu et al. Immunomodulatory activities on RAW 264.7 macrophages of a polysaccharide from veiled lady mushroom, Dictyophora indusiata (higher basidiomycetes)
Matsushima et al. Calcium ionophore (A23187) increases interleukin 1 (IL-1) production by human peripheral blood monocytes and interacts synergistically with IL-1 to augment concanavalin A stimulated thymocyte proliferation
CN106727115A (zh) 一种用于增生性疤痕修复的护肤霜及其制备方法
CN115737470B (zh) 一种肌肽-pdrn复合物及其制备方法和应用
Taylor et al. Partial purification of a 5.7 K glycoprotein from bovine vitreous which inhibits both angiogenesis and collagenase activity
CN108853000A (zh) 具有保湿抗皱恢复肌肤弹性功效的组合物、面膜及其制备方法
Son et al. Characterization of carnosine uptake and its physiological function in human intestinal epithelial Caco‐2 cells
CN113769066A (zh) 一种促进创面愈合的组合物及其制备方法与用途
Yap et al. Immunomodulatory properties of water-soluble polysaccharides extracted from the fruiting body of Chinese caterpillar mushroom, Ophiocordyceps sinensis cultivar OCS02®(Ascomycetes)
EP0106309A3 (de) Biologisch aktive Extrakte, Verfahren zu deren Herstellung, sie enthaltende pharmazeutische und kosmetische Mittel und ihre Verwendung als Zusätze für Lebens- und Genussmittel
Kitano et al. Synthesis of the third component of complement (C3) by human gastric cancer‐derived cell lines
CN119454555A (zh) 一种具有晒后修护和美白功效的组合物及其制备方法
CN109232714A (zh) 一类用于促胶原分泌的超短肽及其应用
Shin et al. Study on Extraction of Mucopolysaccharide-protein Containing Chondroitin Sulfate from Chicken Keel Cartilage Electrophoresis
KR102087187B1 (ko) 피부 개선용 키트

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application